All In Biotech

NDA 210923 · Vancocin Italia

Mulpleta

Lusutrombopag · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 31, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jul 31, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

1 Phase 3, 2 recruiting

FAERS reports

39

27 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 9, 2025.

MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. MULPLETA is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1 )

Mechanism: Lusutrombopag is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 31, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • MULPLETA · LUSUTROMBOPAG 3MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lusutrombopag" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death3
  • drug ineffective3
  • nausea3
  • ascites2
  • diarrhoea2
  • headache2
  • hospitalisation2
  • mesenteric vein thrombosis2
  • pain2
  • pancytopenia2
  • portal vein thrombosis2
  • pulmonary embolism2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20187
201910
20207
20211
20227
20232
20243
20252

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mulpleta (Lusutrombopag)

2024 spending

$205K

Beneficiaries

17

24 claims

Per beneficiary

$12,062

$1,171.73 per unit

View as table
YearSpending
2020$1,020,766
2021$523,751
2022$324,612
2023$277,673
2024$205,053

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Vancocin Italia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.